Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. BioNTech SE is conducting a ...

This study could significantly impact BioNTech’s stock performance and investor sentiment, as successful results may enhance the company’s position in the oncology market. The involvement of ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Shortly after that, the CDC overhauled its vaccine recommendations in COVID, nixing its endorsement of the shots for pregnant women and healthy children. At the time, RFK Jr. said he “couldn’t be more ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

“Stratus,” originally known as Variant XFG, is the second most prominent strain of COVID in the United States. According to ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.